Hepatology Commons^™

Elevated Liver Biochemistries In Hospitalized Chinese Patients With Severe Covid-19: Systematic Review And Meta-Analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, S. K. Satapathy

Journal Articles

BACKGROUND & AIMS:Several recent studies have reported an abnormal liver chemistry profile among patients with coronavirus disease 2019 (COVID-19), although its clinical significance remains unknown. APPROACH & RESULTS:This novel systematic review and meta-analysis identified six studies of 586 patients delineating liver chemistries among patients with severe/critical illness versus mild cases of COVID-19 infection. Patients with severe/critical illness with COVID-19 infection have increased prevalence of coronary artery disease (CAD), cerebrovascular disease, and chronic obstructive pulmonary disease (COPD) as compared to mild cases. A significant association between severe/critical COVID-19 infections with elevations in aspartate aminotransferase (AST) (pooled mean difference [MD], 11.70 U/L; …

Prevalence Of Chronic Liver Disease In Patients With Covid-19 And Their Clinical Outcomes: A Systematic Review And Meta-Analysis, A. J. Kovalic, S. K. Satapathy, P. J. Thuluvath

Journal Articles

No abstract provided.

Role Of Nutraceuticals In Covid-19 Mediated Liver Dysfunction., M. Sikander, S. Malik, A. Rodriguez, M. M. Yallapu, A. S. Narula, S. K. Satapathy, V. Dhevan, S. C. Chauhan, M. Jaggi

Journal Articles

COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread of this deadly virus at incredible speed has stunned the planet and poses a challenge to global scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy is gaining importance and is an area of great concern. Currently, alternatives therapies are being sought to mitigate hepatic damage, and there has been growing interest in the research on bioactive phytochemical agents (nutraceuticals) due to their versatility in health benefits reported …

Association Between Longer Hospitalization And Development Of De Novo Donor Specific Antibodies In Simultaneous Liver–Kidney Transplant Recipients, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, S. Fossey, S. K. Satapathy, J. D. Eason, M. Z. Molnar

Journal Articles

© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Background:De novo Donor Specific Antibodies (DSA) are considered as a risk factor for the kidney allograft outcomes in recipients after simultaneous liver–kidney transplantation (SLKT). We hypothesized that length of hospital stay (LOS) might be associated with de novo DSA development of due to the increased likelihood of receiving blood transfusions with reduced immunosuppressive regimens. Methods: This study is a single-center, retrospective cohort study consisting of 85 recipients who underwent SLKT from 2009 to 2018 in our hospital. We divided the patients into two …

Accuracy Of Noninvasive Fibrosis Scoring Systems In African American And White Patients With Nonalcoholic Fatty Liver Disease, H. K. Marella, Y. K. Reddy, Y. Jiang, S. Ganguli, P. S. Podila, P. D. Snell, A. J. Kovalic, G. Cholankeril, A. K. Singal, S. K. Satapathy, +2 Additional Authors

Journal Articles

No abstract provided.

Prevalence And Profile Of Nonalcoholic Fatty Liver Disease In Lean Adults: Systematic Review And Meta-Analysis., S. Young, R. Tariq, J. Provenza, S. K. Satapathy, K. Faisal, A. Choudhry, S. L. Friedman, A. K. Singal

Journal Articles

Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among individuals who are lean (normal body mass index) is unclear. Published data from studies comparing lean with obese NAFLD or with healthy subjects on prevalence, comorbidities, liver chemistry and histology, and metabolic/inflammatory markers were analyzed. Data were reported as odds ratio and 95% confidence interval for categorical variables and difference of means for continuous variables. Analysis of 53 studies on 65,029 subjects with NAFLD (38,084 lean) and 249,544 healthy subjects showed a prevalence of lean NAFLD at 11.2% in the general population. Among individuals with NAFLD, the prevalence …

Outcomes Of Liver Transplant Recipients With Acute-On-Chronic Liver Failure Based On Easl-Clif Consortium Definition: A Single-Center Study, U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H. Gonzalez, S. K. Satapathy, +3 Additional Authors

Journal Articles

© 2020 Cambridge University Press. All rights reserved. Background. The impact of acute-on-chronic liver failure (ACLF) defined by European Association for the Study of the Liver-Chronic Liver Failure in liver transplant (LT) recipients has not been well characterized. The aim of the study was to assess early posttransplant morbidity and survival of ACLF patients. Methods. Eight hundred twenty-five consecutive LT patients (04/2006-03/2013) were included in a retrospective analysis. Of the 690 evaluable patients, 589 had no ACLF, and the remaining 101 were grouped into ACLF Grades 1-3 (ACLF Grade 1: 50 [49.5%], ACLF Grade 2: 32 [31.7%], and ACLF Grade …

Nafld Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications And The Trends In The United States, C. Gadiparthi, M. Spatz, S. Greenberg, U. Iqbal, S. Kanna, S. K. Satapathy, A. Broder, A. Ahmed

Journal Articles

© 2020 Authors. Nonalcoholic fatty liver disease (NAFLD) is a hepatic mani-festation of metabolic syndrome. The spread of obesity worldwide in pandemic proportions has led to a rapid rise of NAFLD in developed and developing countries alike. There are no approved pharmacological agents to treat steatohepatitis or advanced fibrosis but obeticholic acid recently has shown some promise in phase III trial. Currently, NAFLD is the number one etiology for simultaneous liver and kidney transplantation in the USA, second most common indication for liver transplantation (LT) and projected to become number one very soon. LT for NAFLD poses unique challenges, as …

Racial Disparities In Diagnosis And Prognosis Of Nonalcoholic Fatty Liver Disease, N. S. Samji, P. D. Snell, A. K. Singal, S. K. Satapathy

Journal Articles

No abstract provided.

Longitudinal Renal Function In Liver Transplant Recipients With Acute-On-Chronic Liver Failure, M. Yazawa, B. Maliakkal, S. Nair, P. S. Podila, U. A. Agbim, S. Karri, S. D. Khan, D. Maluf, J. D. Eason, S. K. Satapathy, +1 Additional Author

Journal Articles

No abstract provided.

Liver Injury In Covid-19: The Hepatic Aspect Of The Respiratory Syndrome — What We Know So Far, P. Anirvan, P. Bharali, M. Gogoi, P. J. Thuluvath, S. P. Singh, S. K. Satapathy

Journal Articles

© 2020. All Rights Reserved. The 2019 novel coronavirus disease (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health. Although primarily, the infection causes lung injury, liver enzyme abnormalities have also been reported to occur during the course of the disease. We conducted an extensive literature review using the PubMed database on articles covering a broad range of issues related to COVID-19 and hepatic injury. The present review summarizes available information on the spectrum of liver involvement, the possible mechanisms and risk factors of liver injury due to SARS-CoV-2 …

A Pilot Study Of Ex-Vivo Mri-Pdff Of Donor Livers For Assessment Of Steatosis And Predicting Early Graft Dysfunction, S. K. Satapathy, H. C. Gonzalez, J. Vanatta, A. Dyer, W. Angel, S. S. Nouer, M. Kocak, S. K. Kedia, Y. Jiang, J. D. Eason, +11 Additional Authors

Journal Articles

No abstract provided.

Pro: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes, U. Agbim, S. K. Satapathy

Journal Articles

No abstract provided.

Reduced Length Of Stay In Major Hepatectomy Surgery After Implementation Of An Enhanced Recovery Pathway In The United States Veteran Population, Yvonne Nguyen Md, Marilyn Mcnulty Np, Leopoldo Fernandez Md, Michael R. Kazior Md

Graduate Medical Education (GME) Resident and Fellow Research Day Posters

Introduction

Enhanced recovery after surgery (ERAS) pathways are associated with better postoperative recovery, however, evidence is lacking in major liver surgery, .This study aimed to evaluate the impact of an ERAS pathway in U.S. veterans undergoing major hepatectomy surgery. We hypothesized that the adoption of an ERAS pathway reduces decreased length of stay (LOS).

Methods

After approval from the Hunter Holmes McGuire VA Medical Center IRB, we compared data from consecutive patients undergoing elective open hepatectomy within an ERAS pathway (January 2019-December 2019) to a previous cohort of patients before introduction of ERAS (July 2016-December 2017). One surgeon performed all …

What Gi Physicians Need To Know During Covid-19 Pandemic, P. J. Thuluvath, J. J. Alukal, N. Ravindran, S. K. Satapathy

Journal Articles

No abstract provided.

A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response To Obeticholic Acid In Patients With Nash., Samer Gawrieh, Xiuqing Guo, Jingyi Tan, Marie Lauzon, Kent D Taylor, Rohit Loomba, Oscar W Cummings, Sreekumar Pillai, Pallav Bhatnagar, Kris V Kowdley, Katherine Yates, Laura A Wilson, Yii-Der Ida Chen, Jerome I Rotter, Naga Chalasani

Articles, Abstracts, and Reports

A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid (OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, NASH treatment) trial. However, genetic predictors of response to OCA are unknown. We conducted a genome-wide association study (GWAS) in FLINT participants to identify variants associated with NASH resolution and fibrosis improvement. Genotyping was performed using the Omni2.5 content GWAS chip. To avoid false positives introduced by population stratification, we focused our GWAS on white participants. Six regions on chromosomes 1, 4, 6, 7, 15, and 17 …

Acute Diagnosis Of Wilson’S Disease In A Teenage Patient, Sarah Irvin, Ryan Mccarthy

Marshall Journal of Medicine

Wilson’s Disease, a rare autosomal recessive genetic disease, is caused by a mutation in the ATP7B enzyme gene. Without this enzyme, copper builds up in the brain, liver, and cornea causing a multitude of symptoms. It is important to consider Wilson’s disease because the prognosis is dependent on timely diagnosis. This is an interesting case of a 19-year-old male who presented with suicidal thoughts and rapid weight loss. After many months and an extensive work-up, Wilson’s Disease was diagnosed. Due to his rapid decline, he was transferred to a larger university healthcare center where he is currently enrolled in clinical …

Characterization Of Patients With Both Alcoholic And Nonalcoholic Fatty Liver Disease In A Large United States Cohort., George Khoudari, Amandeep Singh, Mazen Noureddin, Danielle Fritze, Rocio Lopez, Imad Asaad, Eric Lawitz, Fred Poordad, Kris V Kowdley, Naim Alkhouri

Articles, Abstracts, and Reports

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS) and is characterized by steatosis in the absence of significant alcohol consumption. However, MetS and significant alcohol intake coexist in certain individuals which may lead to the development of BAFLD.

AIM: To assess the clinical characteristics of patients with both alcoholic and NAFLD (BAFLD) in a large cohort in the United States.

METHODS: Adults from the National Health and Nutrition Examination Survey between 2003-2014 were included. NAFLD was diagnosed based on elevated alanine aminotransferase (ALT) and being overweight or obese in the absence of other …

Can We Predict Low Quality Colonoscopy? Establishing Open Access Colonoscopy At A Fellow-Run Gastroenterology Clinic, Matthew Sullivan Do, Abdul Aleem Md, Rajesh Essrani Md, Patrick Hickey Do, Robert Andrews Md, Anam Malik Md, Hiral N. Shah Md, Shashin Shah Md

Department of Medicine

No abstract provided.

The Evaluation Of Liver Fibrosis Regression In Chronic Hepatitis C Patients After The Treatment With Direct-Acting Antiviral Agents – A Review Of The Literature, Olga H. Orasan, George Ciulei, Sorina C. Coste, Bianca A. Cibu, Adela V. S Taut, Simina F. Tarmure, Iulia O. Pfingstgraf, Teodora G. Alexescu, Ionela E. Popovici, Flaviu Mureșan, Fabian Ovidiu, Vasile Negrean, Angela Cozma

Journal of Mind and Medical Sciences

The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but the invasiveness of this procedure is its major drawback. Different non-invasive tests have been used to study changes in the stage of liver fibrosis in patients with chronic viral hepatitis treated with the second-generation of direct-acting antiviral agents: liver stiffness measurements (with transient elastography or acoustic radiation force impulse elastography) or different scores that use serum markers to calculate a fibrosis score. We prepared …